RVPH REVIVA PHARMACEUTICALS HLDGS INC

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

Company Webcast

The webcasted presentation will take place at 12:30 p.m. ET on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at or directly at . A replay of the presentation will also be available through same links.

1x1 investor meetings will be available after the event upon request by contacting your Lytham representative at .

About Reviva 

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. 

Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD 

Investor Relations Contact:

LifeSci Advisors, LLC

Bruce Mackle



EN
07/01/2025

Underlying

RVPHREVIVA PHARMACEUTICALS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REVIVA PHARMACEUTICALS HLDGS INC

 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Announces Publication on Clinical Vocal Biomarker Data from the...

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia CUPERTINO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Foru...

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA. ...

December 29, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Announces Regulatory Update Regarding the Development of Brilar...

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package highlights long-term safety profile, broad-spectrum clinical activity, and favorable adherence observed to date for once daily brilaroxazine over up to one year Initiation of RECOVER-2 registrational trial planned in H1 2026, subject t...

December 23, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Reports Third Quarter 2025 Financial Results and Recent Busines...

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights – Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 –  – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – CUPERTINO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical c...

November 13, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizo...

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patien...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch